Nephros, Inc.NEPHNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank72
3Y CAGR-26.5%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-26.5%/yr
Quarterly compound
Percentile
P72
Within normal range
vs 3Y Ago
0.4x
Contraction
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 16.86% |
| Q3 2025 | 8.68% |
| Q2 2025 | 5.42% |
| Q1 2025 | 17.06% |
| Q4 2024 | 34.04% |
| Q3 2024 | -25.98% |
| Q2 2024 | 19.81% |
| Q1 2024 | 1.92% |
| Q4 2023 | 1.46% |
| Q3 2023 | -7.24% |
| Q2 2023 | -7.53% |
| Q1 2023 | -33.43% |
| Q4 2022 | 42.46% |
| Q3 2022 | -7.69% |
| Q2 2022 | -26.61% |
| Q1 2022 | -24.24% |
| Q4 2021 | 24.30% |
| Q3 2021 | -18.89% |
| Q2 2021 | -12.41% |
| Q1 2021 | -8.70% |
| Q4 2020 | -18.91% |
| Q3 2020 | -10.17% |
| Q2 2020 | 48.49% |
| Q1 2020 | -26.31% |
| Q4 2019 | -1.67% |
| Q3 2019 | -2.02% |
| Q2 2019 | 4.89% |
| Q1 2019 | 38.46% |
| Q4 2018 | 55.11% |
| Q3 2018 | 0.00% |
| Q2 2018 | 21.80% |
| Q1 2018 | 12.02% |
| Q4 2017 | 8.86% |
| Q3 2017 | -14.44% |
| Q2 2017 | 19.91% |
| Q1 2017 | -26.90% |
| Q4 2016 | 31.12% |
| Q3 2016 | -5.12% |
| Q2 2016 | -5.58% |
| Q1 2016 | 10.25% |